Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
ARGENX SE (ARGX) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/27/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
07/27/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"SECOND QUARTER 2023 AND RECENT BUSINESS",
"Unaudited Interim Report for the Six Months Ended June 30, 2023"
07/20/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
07/17/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
07/17/2023 6-K Quarterly results
06/30/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"argenx and Zai Lab Announce Approval of VYVGART® for Generalized Myasthenia Gravis in China"
05/05/2023 6-K Quarterly results
Docs: "FORM 6-K",
"argenx Reports First Quarter 2023 Financial Results and Provides Business Update - $218 million in first quarter VYVGART global net product sales - VYVGART received marketing authorization in Israel through partnership with Medison - 88 events achieved in ADHERE trial; topline data now expected in July 2023 - Enrollment completed in ADVANCE-SC and ADDRESS trials; topline data from both expected in fourth quarter of 2023 - Management to host conference call today at 2:30 pm CET Regulated Information/Inside Information May 4, 2023 Amsterdam, the Netherlands – argenx SE , a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its first quarter 2023 financial results and provided a business update. “Throughout the first...",
"Investor Presentation"
05/05/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"argenx announces results of Annual General Meeting of Shareholders Amsterdam, the Netherlands – argenx SE , a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its annual general meeting of shareholders held yesterday. All items on the agenda received a majority of votes in favor except for agenda item 3 . As part of the approved resolutions: · The company's annual report and annual accounts for the financial year ending December 31, 2022 were approved; · Don deBethizy has been re-appointed as non-executive director to the Board of Directors for a term of 2 years; · The Board of Directors was authorized to issue shares and grant rights to subscribe for shares in the share capital of ...",
"Voting Results from the Annual General Meeting of Shareholders held on May 2, 2023"
04/18/2023 6-K Quarterly results
04/17/2023 6-K Quarterly results
03/16/2023 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
03/16/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis"
03/02/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"argenx Announces Planned Transition of Chief Operating Officer · Karen Massey appointed as Chief Operating Officer, effective March 13, 2023 · Keith Woods to retire and serve as Advisor on argenx Board of Directors Amsterdam, the Netherlands — argenx , a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karen Massey will join argenx as Chief Operating Officer, effective March 13, 2023. Ms. Massey will succeed Keith Woods, who will remain at argenx for a transition period to support the launch of subcutaneous efgartigimod, after which he will retire and serve as a strategic advisor on the Commercial Committee of the argenx Board of Directors. “Karen brings extensive commercial launch and leaders...",
"argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update",
"2 3 4 5 6 7 8 10"
02/14/2023 SC 13G/A PRICE T ROWE ASSOCIATES INC reports a 7.2% stake in ARGENX SE - ADR
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A FMR LLC reports a 10% stake in ARGENX SE
02/01/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/30/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director",
"Convocation Notice for the Extraordinary General Meeting of Shareholders of argenx SE to be held on February 27, 2023",
"Explanatory Notes for the Extraordinary General Meeting of Shareholders of argenx SE to be held on February 27, 2023",
"Agenda for the Extraordinary General Meeting of Shareholders of argenx SE to be held on February 27, 2023",
"Proxy Form for the Extraordinary General Meeting to be held on February 27, 2023"
01/27/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod Amsterdam, the Netherlands — argenx , a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration has extended the review of the Biologics License Application for subcutaneous efgartigimod for the treatment of adult patients with generalized myasthenia gravis to June 20, 2023. The FDA notified argenx on January 26, 2023 that information submitted in connection with the ongoing review of the SC efgartigimod BLA constituted a major amendment and requires an extension to allow sufficient time to review. No additional data or studies have been requested at this time. “We are confident in the profile of SC efgar..."
01/09/2023 6-K Quarterly results
12/12/2022 6-K Quarterly results
11/30/2022 6-K Quarterly results
11/22/2022 6-K Quarterly results
10/27/2022 6-K Quarterly results
09/21/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"argenx Submits Biologics License Application to U.S. Food and Drug Administration for Subcutaneous Efgartigimod for Treatment of Generalized Myasthenia Gravis ● Submission package based on positive data from the Phase 3 ADAPT-SC trial demonstrating noninferiority of subcutaneous efgartigimod compared to intravenously administered VYVGART ® based on total immunoglobulin G reduction at day 29 Amsterdam, the Netherlands – September 21, 2022 – argenx SE , a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration for SC efgartigimod for the treatment of generalized myasthenia gravis in adult patients. SC efgartigimod is co-formu...",
"argenx to Highlight Key Programs from Neuromuscular Franchise at Upcoming Medical Meetings"
09/08/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"argenx Appoints Camilla Sylvest to Board of Directors Amsterdam, the Netherlands – argenx , a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held today at 6:30pm CET, Mrs. Camilla Sylvest was appointed as non-executive director to its Board of Directors. Mrs. Sylvest brings strong strategic and operational leadership in the scaling of global commercial pharmaceutical organizations with a specific focus on company culture and sustainability. The voting result and all documents relating to the shareholders’ meeting will be available on the argenx website at www.argenx.com/investors/shareholder-meetings. About argenx argenx is a global immunology company com..."
08/12/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"argenx Announces European Commission Approval of VYVGART™ for the Treatment of Generalized Myasthenia Gravis"
07/28/2022 6-K Quarterly results
06/27/2022 6-K Quarterly results
05/19/2022 6-K Quarterly results
05/05/2022 6-K Quarterly results
03/25/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Underwriting Agreement, among the Company and J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Cowen and Company, LLC and SVB Securities LLC, as representatives of the several Underwriters named therein",
"Opinion of Freshfields Bruckhaus Deringer LLP, Dutch counsel to the registrant",
"argenx announces launch of proposed global offering Breda, the Netherlands — argenx SE , a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced today that it has commenced a global offering of $500 million of ordinary shares, which may be represented by American Depository Shares . The global offering will be comprised of an offering of ordinary shares represented by ADSs in the United States and certain other countries outside of the European Economic Area and a simultaneous private placement of ordinary shares in the European Economic Area and the United Kingdom. Each of the ADSs represents the right to receive one ordinary share, nominal value of €0.10 per share. The U.S. offering and the European private placemen...",
"argenx raises $700 million in gross proceeds in a global offering March 23, 2022, 8:30 PM ET March 24, 2022, 1:30 AM CET Breda, the Netherlands — argenx SE , a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced today the pricing of a global offering of ordinary shares represented by American Depository Shares in the United States and certain other countries outside of the European Economic Area and a simultaneous private placement of ordinary shares in the European Economic Area and the United Kingdom. The Company anticipates total gross proceeds of approximately $700 million from the sale of 1,551,044 ADSs at a price of $300.00 per ADS and the sale of 782,290 ordinary shares at a price of €273.10 per ordinary shar..."
03/25/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/22/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy